Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Last updated: March 5, 2024
Sponsor: M.D. Anderson Cancer Center
Overall Status: Trial Not Available

Phase

2

Condition

Prostate Cancer

Prostate Cancer, Early, Recurrent

Prostate Disorders

Treatment

Gallium Ga 68-labeled PSMA-11

Computed Tomography

Positron Emission Tomography

Clinical Study ID

NCT05034562
2019-1203
2019-1203
NCI-2020-03699
  • Ages > 18
  • Male

Study Summary

This phase II trial studies how well gallium-68 PSMA-11 PET/CT or PET/MRI works in finding prostate cancer cells that have come back (recurrent) in patients with prostate cancer. Gallium-68 PSMA-11 is a type of radioactive compound, called a radiotracer, which is injected in the vein and can accumulate in tumor cells to generate a signal detected by PET/CT or PET/MRI imaging. This may help researchers in finding recurrent prostate cancer cells in patients with prostate cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pathologically proven prostate cancer
  • Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy orradiation therapy (external beam or brachytherapy)
  • Karnofsky performance status (KPS) >= 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] 0, 1, or 2)
  • Ability to understand and willingness to provide informed consent
  • Participants with known metastatic prostate cancer planned to undergo active systemictreatment

Exclusion

Exclusion Criteria:

  • Unable to lie flat, still, or tolerate a PET or MRI scan
  • Contraindication to optional furosemide administration including prior allergy oradverse reaction to furosemide or sulfa drugs. This exclusion criteria can be removedif furosemide is omitted as part of the PET imaging protocol if a second-generationscatter correction - (defined as either Ga-68 specific prompt gamma correction ormultiple scatter model) is available for the used PET device

Study Design

Treatment Group(s): 4
Primary Treatment: Gallium Ga 68-labeled PSMA-11
Phase: 2
Study Start date:
September 26, 2022
Estimated Completion Date:
September 26, 2022

Study Description

PRIMARY OBJECTIVE:

I. To assess the positive predictive value (PPV) of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA11) positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI) on a patient level using histopathology or confirmatory imaging as a standard of truth (SoT).

SECONDARY OBJECTIVES:

I. To assess the PPV per-patient for 68Ga-PSMA-11 PET/CT and PET/MRI detection of tumor location confirmed by histopathology/biopsy alone.

II. Demonstrate the safety of 68Ga-PSMA-11 PET/CT or PET/MRI imaging in participants with prostate cancer.

III. Demonstrate the efficacy of 68Ga-PSMA-11 PET/CT or PET/MRI imaging to monitor response to treatment in participants with prostate cancer.

OUTLINE:

Patients receive gallium 68Ga-PSMA-11 intravenously (IV). 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.

After completion of study, patients are followed up at 30 and 90 days, then between 3-36 months.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.